Christian Selinger
Overview
Explore the profile of Christian Selinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tessandier N, Elie B, Boue V, Selinger C, Rahmoun M, Bernat C, et al.
PLoS Biol
. 2025 Jan;
23(1):e3002949.
PMID: 39836629
Human papillomavirus (HPV) infections drive one in 20 new cancer cases, exerting a particularly high burden on women. Most anogenital HPV infections are cleared in less than two years, but...
2.
Beneteau T, Groc S, Murall C, Boue V, Elie B, Tessandier N, et al.
Infect Dis (Lond)
. 2024 Nov;
:1-10.
PMID: 39608970
Background: We studied the duration of HPV detection and risk of (re-) detection for 25 HPV genotypes in a cohort of 132 women followed every eight weeks for up to...
3.
Selinger C, Laube R, Limdi J, Headley K, Kent A, Kok K, et al.
Therap Adv Gastroenterol
. 2024 Nov;
17:17562848241299737.
PMID: 39539488
Background: Many women of childbearing age with inflammatory bowel disease (IBD) require advanced therapies. While biologics are largely low risk during pregnancy, the novel small molecules tofacitinib, filgotinib, upadacitinib and...
4.
Parigi T, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, et al.
United European Gastroenterol J
. 2024 Oct;
12(9):1266-1279.
PMID: 39367753
Background: Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized...
5.
Al Sulais E, Louis E, Bokemeyer B, Gecse K, Parkes G, Parkes M, et al.
J Crohns Colitis
. 2024 Sep;
19(2).
PMID: 39243391
Background And Aims: Corticosteroids are widely used in managing inflammatory bowel disease (IBD). While adverse events (AEs) of corticosteroids are well recognized, current understanding of corticosteroid-related AE burden in IBD...
6.
Selinger C, van der Meulen A
J Clin Med
. 2024 Aug;
13(16).
PMID: 39200841
The treatment goal for patients with Crohn's disease (CD) has traditionally been aimed at symptomatic steroid-free clinical remission [...].
7.
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients
Gebeyehu G, Broglio G, Liu E, Limdi J, Selinger C, Fiske J, et al.
Inflamm Bowel Dis
. 2024 Aug;
PMID: 39096528
Background: Biologic therapies are associated with increased infection risk among elderly patients with inflammatory bowel disease (IBD). However, there are few data on the safety and effectiveness of ustekinumab compared...
8.
Selinger C, Bottle A, Lamb C, Ainley R, Wakeman R, Hawthorne B
Frontline Gastroenterol
. 2024 Apr;
15(3):228-232.
PMID: 38665788
Background: Key performance indicators (KPIs) are required to facilitate quality improvement for inflammatory bowel disease (IBD). Emergency admissions for IBD may represent a possible KPI. Methods: IBD emergency admissions for...
9.
Baillie S, Limdi J, Bassi A, Fraser A, Parkes G, Scott G, et al.
Frontline Gastroenterol
. 2023 Oct;
14(6):497-504.
PMID: 37854782
Objective: Despite its association with poorer outcomes, opioid use in inflammatory bowel disease (IBD) is not well characterised in the UK. We aimed to examine the extent of opioid use,...
10.
Lim S, Gros B, Sharma E, Lehmann A, Lindsay J, Caulfield L, et al.
Inflamm Bowel Dis
. 2023 Aug;
30(8):1284-1294.
PMID: 37603730
Background And Aims: Despite intravenous (IV) vedolizumab being established for treatment of inflammatory bowel disease (IBD), the novel subcutaneous (SC) route of administration may provide numerous incentives to switch. However,...